Accuri C6 Flow Cytometer System
A more recent version of this article appeared on April 1, 2004

Published online before print January 2, 2004
This Article
Right arrow Full Text (Reprint (PDF))
Right arrow All Versions of this Article:
jlb.1003454v1
75/4/624    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rose, B.
Right arrow Articles by Martin, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rose, B.
Right arrow Articles by Martin, S.
© by The Society for Leukocyte Biology
Journal of Leukocyte Biology, doi:10.1189/jlb.1003454

Received for publication October 1, 2003.
Revised December 4, 2003.
Accepted for publication December 8, 2003.

Article

Combined activation of innate and T cell immunity for recognizing immunomodulatory properties of therapeutic agents

Bettina Rose , Christian Herder , Heike Löffler , Hubert Kolb , and Stephan Martin @

German Diabetes Research Institute at the Heinrich-Heine-University Düsseldorf, Germany

@ To whom correspondence should be addressed. E-mail: martin{at}ddfi.uni-duesseldorf.de.


arrow
Abstract

Complex syndromes such as atherosclerosis and type 2 diabetes are disorders that are associated with inflammatory processes involving innate and adaptive immunity. Emerging knowledge about the pathological consequences of immune imbalances in a wide range of disease settings is expected to help to identify novel therapeutic targets. However, current test systems for immunomodulatory drugs tend to be too simplistic, as they rely only on cells of the innate- or the adaptive-immune system, or they are complex, in vivo models, which are not suitable for screening purposes. Using a modified mixed lymphocyte culture (MMLC) assay for combined analysis of innate and adaptive immunity, we show that this assay is very sensitive for the presence of low concentrations of immunomodulatory agents. Low-dose lipopolysaccharide stimulation of cells from two unrelated donors yields a strong cytokine response including interleukin (IL)-12 and IL-18, which induce interferon-{gamma} as a potential analysis parameter. As the MMLC assay is based on the mutual interaction of cells of the innate and adaptive immunity, it enables the monitoring of cytokine release under almost physiological conditions and might be of interest for the characterization of known and novel drugs concerning their immunomodulatory potency.

Key Words: immunomodulation • immune mediators • LPS • adaptive immunity




This article has been cited by other articles:


Home page
 EndocrinologyHome page
T. Skurk, C. Herder, I. Kraft, S. Muller-Scholze, H. Hauner, and H. Kolb
Production and Release of Macrophage Migration Inhibitory Factor from Human Adipocytes
Endocrinology, March 1, 2005; 146(3): 1006 - 1011.
[Abstract] [Full Text] [PDF]